CBIO
Crescent Biopharma
CBIO
CBIO
78 hedge funds and large institutions have $110M invested in Crescent Biopharma in 2021 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 26 increasing their positions, 25 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
28% less call options, than puts
Call options by funds: $594K | Put options by funds: $826K
58% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 19
Holders
78
Holding in Top 10
–
Calls
$594K
Puts
$826K
Top Buyers
| 1 | +$2.51M | |
| 2 | +$2.01M | |
| 3 | +$1.07M | |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$638K |
| 5 |
BlackRock
New York
|
+$623K |
Top Sellers
| 1 | -$8.27M | |
| 2 | -$3.38M | |
| 3 | -$1.88M | |
| 4 |
Morgan Stanley
New York
|
-$1.04M |
| 5 |
Millennium Management
New York
|
-$519K |